摘要:
Mammalian synovial phospholipase A.sub.2 (sPLA.sub.2) enzymes are provided, as well as DNA constructs encoding these enzymes, methods of producing the enzymes recombinantly, and antibodies thereto. Therapeutic methods employing anti-synovial phospholipase antibodies are also provided, in addition to diagnositc methods and other applications of sPLA.sub.2.
摘要:
Antibodies that specifically bind to and inhibit the enzymatic activity of synovial phospholipase A.sub.2 Type A are described. The antibodies may be used in assays for detection of synovial phospholipase A.sub.2 in biological samples.
摘要:
Cloning and expression of the gene encoding human phosphlipase inhibitory protein (hPIP) permits production of an anti-inflammatory protein in practical quantities using recombinant techniques.
摘要:
Methods and compositions are provided for inducing natriuresis, diuresis and vasodilatation in mammalian hosts by administering atrial natriuretic/vasodilator polypeptides to said host. Also provided are methods for producing such polypeptides, and antibodies which are capable of recognizing and specifically binding to them.
摘要:
A method of increasing the bioavailability of 5-aminosalicylate compound by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of 5-aminosalicylate compound in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food.
摘要:
Compounds and compositions comprising synthetic analogs of Atrial Natriuretic Peptides are provided, together with methods for their production and use as natriuretics, diuretics and/or vasodilators, or as intermediates for or modulators of such useful compounds or of native Atrial Natriuretic Peptides.
摘要:
The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.
摘要:
Compounds and compositions comprising cyclic synthetic analogs of Atrial Natriuretic Peptides are provided, together with methods for their production and use as natriuretics, diuretics and/or vasodilators, or as intermediates for or modulators of such useful compounds or of native Atrial Natriuretic Peptides.